How to Manage Relapsed FLT3-positive AML

By Blood Cancer Talks - Last Updated: December 6, 2023

In the latest episode of Blood Cancer Talks, Alexander Perl, MD, of the University of Pennsylvania, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; to discuss the management of newly diagnosed and relapsed FLT3-positive acute myeloid leukemia (AML).

Dr. Perl and the hosts also discuss the QuANTUM-First trial, which studied quizartinib plus chemotherapy in newly diagnosed patients with FLT3 internal-tandem-duplication-positive AML; the benefit of high-dose daunorubicin in AML induction across cytogenetic and molecular groups; sorafenib maintenance in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem-cell transplantation; and more.

This podcast originally appeared on Blood Cancer Talks.

Dr. Schmidt on Quadruplet Therapy for Newly Diagnosed, Transplant Ineligible MM

Discussing Lower-Risk MDS Treatment Options With Dr. Stahl

Dr. Gerds on the Treatment of Polycythemia Vera

Dr. Iacoboni Highlights Key Lymphoma Abstracts Presented This Year

MRD Use in Multiple Myeloma: Clinical Practice, Clinical Trials, and Drug Approval

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

How to Manage Relapsed FLT3-positive AML

Related